Head-to-head dispatch
FORM by GBY vs Sprout Health
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
The broadest menu in the ranking — compounded and branded GLP-1s, NAD+/sermorelin, and hair loss on one account — but the advertised Wegovy "$95/mo" is a membership fee only, not the drug cost.
Marked down on: The advertised Wegovy "$95/mo" is a MEMBERSHIP FEE ONLY — the medication cost is billed separately and undisclosed; do not read $95 as the all-in price
Desk Score
A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
Marked down on: FDA issued Sprout Health Partners LLC dba Sprout Health a warning letter in September 2025; the letter is public in FDA's warning-letter database
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
Sprout Health takes this head-to-head with the higher Desk Score, 86/100 (B) against 68/100 (C) for FORM by GBY. FORM by GBY still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
FORM by GBY
68/100
C
Sprout Health
86/100
B
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | FORM by GBY | Sprout Health |
|---|---|---|
| Semaglutide | $299/mo (compounded, no dose tiers published) | $299/mo |
| Tirzepatide | Not disclosed (Zepbound membership offered, drug cost not published) | $349/mo |
| Coverage | 48 states + DC (excludes Alaska, Mississippi) | Not disclosed |
| Brand-name | Yes | Yes |
| Oral option | Yes | Injectable only |
| Best for | Patients who want the widest single-account menu and are willing to complete intake to learn what the branded and adjacent-care lines actually cost. | Patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding. |
| Desk Score | 68/100C | 86/100B |
The verdict
Desk pick — Sprout HealthSprout Health takes this head-to-head with the higher Desk Score, 86/100 (B) against 68/100 (C) for FORM by GBY. FORM by GBY still holds its ground where its strengths line up with yours.
Choose FORM by GBY if…
Patients who want the widest single-account menu and are willing to complete intake to learn what the branded and adjacent-care lines actually cost.
$299/mo (compounded, no dose tiers published) sema · Not disclosed (Zepbound membership offered, drug cost not published) tirz · 48 states + DC (excludes Alaska, Mississippi)
Choose Sprout Health if…
Patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding.
$299/mo sema · $349/mo tirz · Not disclosed
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: FORM by GBY · Sprout Health.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- FORM by GBY vs CoreAge Rx
- Sprout Health vs Vaylen
- FORM by GBY vs Strut Health
- Sprout Health vs Ondra Health
- FORM by GBY vs Invigor Medical
- Sprout Health vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.